keyword
MENU ▼
Read by QxMD icon Read
search

Olmesartan

keyword
https://www.readbyqxmd.com/read/29115506/angiotensin-ii-induces-monocyte-chemoattractant-protein%C3%A2-1-expression-by-increasing-reactive-oxygen-species%C3%A2-mediated-activation-of-the-nuclear-factor%C3%A2-%C3%AE%C2%BAb-signaling-pathway-in-osteoblasts
#1
Changyao Wang, Cailong Zhang, Feng Zhou, Lei Gao, Yingzhen Wang, Chunsheng Wang, Yongtao Zhang
The present study investigated the effect of angiotensin II (Ang II) on monocyte chemoattractant protein‑1 (MCP‑1) expression and the underlying mechanism in osteoblasts. MCP‑1 expression levels were analyzed by ELISA and reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR). Ang II type 1 receptor (AT1R) expression levels was examined by RT‑qPCR, western blotting and immunostaining. In addition, the nuclear factor (NF)‑κB signaling pathway was investigated via western blot analysis...
November 6, 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/29105106/angiotensin-receptor-blocker-use-and-gastro-oesophageal-cancer-survival-a-population-based-cohort-study
#2
J Busby, Ú McMenamin, A Spence, B T Johnston, C Hughes, C R Cardwell
BACKGROUND: Angiotensin receptor blockers (ARBs; including candesartan, losartan, olmesartan and valsartan) are widely used to treat hypertension, heart failure and diabetic neuropathy. There is considerable pre-clinical evidence that ARBs can reduce cancer progression, particularly for gastric cancer. Despite this, epidemiological studies have yet to assess the impact of ARB use on gastro-oesophageal cancer survival. AIM: To investigate the association between post-diagnosis ARB use and gastro-oesophageal cancer survival...
November 3, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29092961/maternal-olmesartan-exposure-causing-neonatal-failure
#3
Antonio Pérez-Iranzo, Ana Nos Ferreres, Aranzazu Jarque Bou
Although angiotensin II receptor blockers (ARBs) are contraindicated during pregnancy, new cases are currently being reported.A 32-week preterm neonate was admitted after C-section due to maternal oligohydramnios. He presented with Potter phenotype, pulmonary hypoplasia with pneumothorax, systemic hypotension and anuria. He required chest drain insertion and continuous positive airway pressure (CPAP), volume expansion plus inotropic support with persistent renal failure. Mother confirmed olmesartan intake during entire pregnancy...
November 1, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/29081617/efficacy-and-tolerability-of-olmesartan-telmisartan-and-losartan-in-patients-of-stage-i-hypertension-a-randomized-open-label-study
#4
Mrunalini Kalikar, Kundan S Nivangune, Ganesh N Dakhale, Chaitali S Bajait, Smita D Sontakke, Vijay M Motghare, Ritu Budania
OBJECTIVES: To compare the efficacy and tolerability of losartan, telmisartan, and olmesartan as antihypertensive agents and evaluate and compare their effects on lipid profile and blood glucose. MATERIALS AND METHODS: This was a randomized, open-label, parallel-group, comparative study conducted in sixty patients of Stage I hypertension. The eligible patients were randomly allocated into three treatment groups: (1) Tablet olmesartan (20 mg), (2) Tablet telmisartan (40 mg), and (3) Tablet losartan (50 mg)...
July 2017: Journal of Pharmacology & Pharmacotherapeutics
https://www.readbyqxmd.com/read/29067756/olmesartan-based-monotherapy-vs-combination-therapy-in-hypertension-a-meta-analysis-based-on-age-and-chronic-kidney-disease-status
#5
Prakash Deedwania, Michael Weber, Paul-Egbert Reimitz, George Bakris
Antihypertensive monotherapy is often insufficient to control blood pressure (BP). Several recent guidelines advocate for initial combination drug therapy in many patients. This meta-analysis of seven randomized, double-blind studies (N = 5888) evaluated 8 weeks of olmesartan medoxomil (OM)-based single-pill dual-combination therapy (OM+amlodipine/azelnidipine or hydrochlorothiazide) vs OM monotherapy in adults with hypertension. BP-lowering efficacy, goal achievement, and adverse events were assessed in the full cohort and subgroups (elderly/nonelderly and patients with and without chronic kidney disease)...
October 25, 2017: Journal of Clinical Hypertension
https://www.readbyqxmd.com/read/29049981/angiotensin-receptor-blockade-improves-cardiac-mitochondrial-activity-in-response-to-an-acute-glucose-load-in-obese-insulin-resistant-rats
#6
Max Thorwald, Ruben Rodriguez, Andrew Lee, Bridget Martinez, Janos Peti-Peterdi, Daisuke Nakano, Akira Nishiyama, Rudy M Ortiz
Hyperglycemia increases the risk of oxidant overproduction in the heart through activation of a multitude of pathways. Oxidation of mitochondrial enzymes may impair their function resulting in accumulation of intermediates and reverse electron transfer, contributing to mitochondrial dysfunction. Furthermore, the renin-angiotensin system (RAS) becomes inappropriately activated during metabolic syndrome, increasing oxidant production. To combat excess oxidant production, the transcription factor, nuclear factor erythriod-2- related factor 2 (Nrf2), induces expression of many antioxidant genes...
October 7, 2017: Redox Biology
https://www.readbyqxmd.com/read/29048242/qbd-driven-development-and-evaluation-of-nanostructured-lipid-carriers-nlcs-of-olmesartan-medoxomil-employing-multivariate-statistical-techniques
#7
Sarwar Beg, Sumant Saini, Shantanu Bandopadhyay, O P Katare, Bhupinder Singh
PURPOSE: The current research work entails Quality by Design (QbD)-based systematic development of nanostructured lipid carriers (NLCs) of olmesartan medoxomil (OLM) with improved biopharmaceutical attributes. METHODS: Quality target product profile (QTPP) was defined and critical quality attributes (CQAs) were earmarked. Solubility of drug was performed in various lipids for screening of them. NLCs were prepared by hot-microemulsion method using solid lipids, liquid lipids and surfactants with maximal solubility...
October 19, 2017: Drug Development and Industrial Pharmacy
https://www.readbyqxmd.com/read/29045341/effect-of-antihypertensive-treatment-on-24-h-blood-pressure-variability-pooled-individual-data-analysis-of-ambulatory-blood-pressure-monitoring-studies-based-on-olmesartan-mono-or-combination-treatment
#8
Stefano Omboni, Kazuomi Kario, George Bakris, Gianfranco Parati
OBJECTIVE: To evaluate the impact of olmesartan alone or combined with one to three antihypertensive drugs on 24-h blood pressure variability (BPV) and on distribution of BP reduction in a pooled individual data analysis of 10 double-blind, randomized, ambulatory BP monitoring (ABPM) studies. METHODS: ABPMs were performed before and after 6-12 weeks of treatment with placebo (n = 119), active control monotherapy [n = 1195, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), dihydropyridine calcium channel blockers (DCCBs)], or DCCBs), olmesartan monotherapy (n = 1410), active control dual combination [n = 79, DCCB + thiazide diuretic (TD)], olmesartan dual combination (n = 637, DCCB or TD), and triple combination therapy (n = 102, DCCB+TD)...
October 16, 2017: Journal of Hypertension
https://www.readbyqxmd.com/read/29035939/predictors-for-the-development-of-microalbuminuria-and-interaction-with-renal-function
#9
Christos Chatzikyrkou, Jan Menne, Joseph Izzo, Giancarlo Viberti, Ton Rabelink, Luis M Ruilope, Christian Rump, Peter R Mertens, Hermann Haller
AIM: It is important to know which factors predict the development of microalbuminuria in patients with diabetes mellitus type II. MATERIAL: Data from the Randomized Olmesartan and Diabetes Microalbuminuria Prevention Study were used to identify predictors for the new onset of microalbuminuria. Furthermore, the interaction of baseline albuminuria and baseline estimated glomerular filtration rate (eGFR) and the effects of treatment with olmesartan were investigated...
October 13, 2017: Journal of Hypertension
https://www.readbyqxmd.com/read/29029087/the-effect-of-sacubitril-valsartan-compared-to-olmesartan-on-cardiovascular-remodelling-in-subjects-with-essential-hypertension-the-results-of-a-randomized-double-blind-active-controlled-study
#10
Roland E Schmieder, Frank Wagner, Michael Mayr, Christian Delles, Christian Ott, Christian Keicher, Maja Hrabak-Paar, Tobias Heye, Solveig Aichner, Yasser Khder, Denise Yates, Diego Albrecht, Thomas Langenickel, Patrick Freyhardt, Rolf Janka, Jens Bremerich
Aims: Progressive aortic stiffening eventually leads to left ventricular (LV) hypertrophy and heart failure if left untreated. Anti-hypertensive agents have been shown to reverse this to some extent. The effects of sacubitril/valsartan (LCZ696), a dual-action angiotensin receptor blocker (ARB), and neprilysin inhibitor, on arterial stiffness and LV remodelling have not been investigated. Methods and results: This was a randomized, multi-centre, double-blind, double-dummy, active-controlled, parallel group, study to compare the effects on cardiovascular remodelling of sacubitril/valsartan with those of olmesartan in patients with hypertension and elevated pulse pressure...
September 27, 2017: European Heart Journal
https://www.readbyqxmd.com/read/28993259/regional-patterns-of-olmesartan-prescription-and-the-prevalence-of-duodenal-villous-atrophy-throughout-the-united-states
#11
Eugenia N Uche-Anya, Peter H R Green, Robert M Genta, Benjamin Lebwohl
No abstract text is available yet for this article.
October 6, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28992296/efficacy-and-safety-of-sacubitril-valsartan-lcz696-compared-with-olmesartan-in-elderly-asian-patients-%C3%A2-65-years-with-systolic-hypertension
#12
Ouppatham Supasyndh, Jian'an Wang, Kudsia Hafeez, Ying Zhang, Jack Zhang, Hiromi Rakugi
OBJECTIVE: Systolic hypertension is common in elderly patients and remains a challenge to treat effectively. The efficacy and safety of sacubitril/valsartan (LCZ696), a first-in-class angiotensin receptor neprilysin inhibitor, vs. olmesartan was evaluated in elderly Asian patients (≥65 years) with systolic hypertension. METHODS: In this randomized, double-blind, 14-week study, patients initially received once-daily sacubitril/valsartan 100 mg or olmesartan 10 mg, increased to sacubitril/valsartan 200 mg or olmesartan 20 mg at week 4...
November 6, 2017: American Journal of Hypertension
https://www.readbyqxmd.com/read/28944989/the-combination-of-valsartan-and-sacubitril-in-the-treatment-of-hypertension-and-heart-failure-an-update
#13
REVIEW
Peter Munch Nielsen, Daniela Grimm, Markus Wehland, Ulf Simonsen, Marcus Krüger
A novel antihypertensive drug, LCZ696 (Entresto®), has recently been introduced, which combines the action of an antagonist of the renin-angiotensin-aldosterone system (RAAS), effectively decreasing the blood pressure, with an inhibition of neprilysin, which is responsible for metabolizing natriuretic peptides exerting antihypertensive and antifibrotic effects. In this MiniReview, we describe the pharmacokinetics and pharmacodynamics, efficacy and side effects of the combined angiotensin receptor antagonist and neprilysin inhibitor LCZ696...
September 25, 2017: Basic & Clinical Pharmacology & Toxicology
https://www.readbyqxmd.com/read/28904053/cardiovascular-biomarkers-in-hypertensive-patients-with-medical-treatment-results-from-the-randomized-teamsta-protect-i-trial
#14
Annika Jagodzinski, Johannes Tobias Neumann, Francisco Ojeda, Nils Arne Sörensen, Philipp Wild, Thomas Münzel, Tanja Zeller, Dirk Westermann, Stefan Blankenberg
BACKGROUND: High blood pressure (BP) is associated with an increased rate of cardiovascular events and mortality. Cardiovascular biomarkers are able to predict long-term risk in the general population, particularly in diseased cohorts. We undertook an investigation of the effect of 2 different antihypertensive treatments on cardiovascular biomarkers in a randomized trial. METHODS: The TEAMSTA study included 481 hypertensive patients. They were randomized to either 80-mg telmisartan + 5-mg amlodipine (TA) or 40-mg olmesartan + 12...
September 13, 2017: Clinical Chemistry
https://www.readbyqxmd.com/read/28871467/epigallocatechin-gallate-protects-against-homocysteine-induced-vascular-smooth-muscle-cell-proliferation
#15
Xiao Li Zhan, Xiu Hong Yang, Yan Hong Gu, Li Li Guo, Hui Min Jin
Epigallocatechin gallate (EGCG), a bioactive ingredient of green tea, plays a protective role in the cardiovascular system. Homocysteine (Hcy) is a major risk factor for chronic kidney disease and cardiovascular disease. The present study aimed to investigate the role of EGCG in Hcy-induced proliferation of vascular smooth muscle cells (VSMCs) and its underlying mechanism. We also explored the roles of rennin-angiotensin system (RAS), extracellular signal-regulated kinases (ERK1/2), and p38 mitogen-activated protein kinase (p38 MAPK) in this process...
September 4, 2017: Molecular and Cellular Biochemistry
https://www.readbyqxmd.com/read/28868495/sprue-like-enteropathy-associated-with-olmesartan-an-unrecognized-emerging-drug-induced-enteropathy
#16
Luís Carvalho Lourenço, Joana Carvalho E Branco, Liliana Santos, Alexandra Martins, Jorge Reis
No abstract text is available yet for this article.
November 2016: GE Port J Gastroenterol
https://www.readbyqxmd.com/read/28828980/single-pill-triple-fixed-dose-combination-therapy-with-single-component-drug-monitoring-in-treatment-resistant-hypertension-a-pilot-study
#17
Reinhold Kreutz, Jurgen Scholze, Antonios Douros
BACKGROUND: Single-pill fixed dose combination (FDC) therapies are widely used in the treatment of arterial hypertension. OBJECTIVE: This pilot study aimed to evaluate the effects of a FDC therapy combined with therapeutic drug monitoring (TDM) on blood pressure (BP) in patients with treatment resistant hypertension. METHOD: The study population included patients with suspected treatment-resistant hypertension during treatment with at least 3 antihypertensive drugs...
August 21, 2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28814846/erratum-olmesartan-vs-ramipril-in-the-treatment-of-hypertension-and-associated-clinical-conditions-in-the-elderly-a-reanalysis-of-two-large-double-blind-randomized-studies-at-the-light-of-the-most-recent-blood-pressure-targets-recommended-by-guidelines-corrigendum
#18
https://www.readbyqxmd.com/read/28793821/the-effects-of-lcz696-in-patients-with-hypertension-compared-with-angiotensin-receptor-blockers-a-meta-analysis-of-randomized-controlled-trials
#19
Yang Zhao, Heng Yu, Xu Zhao, Ruixin Ma, Ningyin Li, Jing Yu
LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, has been demonstrated to have greater advantages in the treatment of heart failure compared with angiotensin-converting enzyme inhibitors, enalapril, or angiotensin receptor blockers (ARBs). However, studies that compared the efficacy and safety of LCZ696 against valsartan in patients with hypertension are limited. To provide further evidence for the benefits of LCZ696 and to make this assessment, a meta-analysis of randomized controlled trials (RCTs) was performed...
September 2017: Journal of Cardiovascular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28706558/qiliqiangxin-enhances-cardiac-glucose-metabolism-and-improves-diastolic-function-in-spontaneously-hypertensive-rats
#20
Jingfeng Wang, Zhiming Li, Yanyan Wang, Jingjing Zhang, Weipeng Zhao, Mingqiang Fu, Xueting Han, Jingmin Zhou, Junbo Ge
Cardiac diastolic dysfunction has emerged as a growing type of heart failure. The present study aims to explore whether Qiliqiangxin (QL) can benefit cardiac diastolic function in spontaneously hypertensive rat (SHR) through enhancement of cardiac glucose metabolism. Fifteen 12-month-old male SHRs were randomly divided into QL-treated, olmesartan-treated, and saline-treated groups. Age-matched WKY rats served as normal controls. Echocardiography and histological analysis were performed. Myocardial glucose uptake was determined by (18)F-FDG using small-animal PET imaging...
2017: Evidence-based Complementary and Alternative Medicine: ECAM
keyword
keyword
11664
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"